ICCM IceCure Medical Ltd. Annual reports only
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1584371 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY2.7%
TTM net income YoY1.7%
TTM EPS YoY-20.0%
Revenue 3-yr CAGR3.1%
Net income 3-yr CAGR—
Margins
Gross margin36.3%
Operating margin-446.7%
Net margin-445.6%
FCF margin-432.4%
EBITDA margin-438.0%
Returns
ROE-188.8%
ROA-113.8%
ROIC (approx.)—
Asset turnover0.26x
Leverage & solvency
Liabilities / assets34.8%
Debt / equity0.00x
Current ratio2.61x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.38M | $3.29M |
| Cost of revenue | $2.15M | $1.84M |
| Gross profit | $1.23M | $1.45M |
| R&D expense | $7.43M | $7.10M |
| SG&A expense | $4.53M | $3.75M |
| Operating income | -$15.09M | -$15.70M |
| Net income | -$15.06M | -$15.32M |
| EBITDA | -$14.80M | -$15.36M |
| EPS (basic) | 0.24 | 0.30 |
| EPS (diluted) | 0.24 | 0.30 |
| Weighted avg. shares (diluted) | 63.58M | 50.88M |
| Balance sheet | ||
| Cash & equivalents | $8.90M | $7.56M |
| Receivables | $331,000 | $221,000 |
| Inventory | $2.62M | $1.99M |
| Current assets | $12.61M | $10.75M |
| PP&E, net | $993,000 | $1.25M |
| Total assets | $13.89M | $12.58M |
| Current liabilities | $4.82M | $5.51M |
| Long-term debt | $13,000 | $161,000 |
| Total debt | $13,000 | $161,000 |
| Total liabilities | $4.84M | $5.67M |
| Shareholders' equity | $9.05M | $6.90M |
| Net debt | -$8.88M | -$7.40M |
| Shares outstanding | 73.12M | 56.57M |
| Cash flow statement | ||
| Operating cash flow | -$14.57M | -$12.56M |
| Capital expenditure | $36,000 | $71,000 |
| Free cash flow | -$14.61M | -$12.63M |
| Investing cash flow | -$36,000 | $446,000 |
| Financing cash flow | $15.83M | $9.19M |
| Depreciation & amortization | $295,000 | $332,000 |
| Stock-based compensation | $1.37M | $869,000 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.